Inseego Brings Flexible Multi-WAN Resilience to Wireless Broadband Offerings 
Indonesia Urges Greater Transparency in Cross-Border Copyright Royalty Governance Before 35 Countries Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism
– Notice of allowance received by Company’s licensor, The University of Sheffield (UK) bolsters intellectual…
Codex DNA to Report Fourth Quarter 2021 Financial Results on Tuesday, March 22, 2022
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer…
Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio
Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue…
Mersana Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage…
Icosavax to Participate in the Cowen 42nd Annual Health Care Conference
SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging…
Supernus to Participate in Annual Cowen Health Care Conference
ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
CAMBRIDGE, Mass. and NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
Gracell Biotechnologies to Report Fourth Quarter & Full Year 2021 Financial Results on Monday, March 14, 2022
PALO ALTO, Calif. and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc….
Alimera Sciences to Present at the Q1 Investor Summit Conference
ATLANTA, March 02, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global…
Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage…
Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference
WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage…
Molecular Templates Strengthens Board of Directors and Management Team
Industry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General…
Ceapro Bolsters Board of Directors with Appointment of Top Executive from Global Pharmaceutical Industry
Ronnie Miller, President and CEO of Roche Canada from 2000-2022 retiring after 43 years of…
AmMax Bio Announces Positive Phase 2 Results Demonstrating Proof-of-Concept for the Novel Local Delivery of AMB-05X in Patients with Tenosynovial Giant Cell Tumor (TGCT)
Intra-Articular Injection Strategy Shows Efficacy Across Multiple Clinical Endpoints and Favorable Safety Profile After 12…
Longeveron to Present at Q1 Virtual Investor Summit Conference
MIAMI, March 02, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical…
Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer
NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Nasdaq: CADL), a late…
Owkin welcomes leading immuno-oncology professor as Chief Medical Officer and senior pharma exec as SVP Data Science
Featured Image for Owkin Featured Image for Owkin NEW YORK, March 02, 2022 (GLOBE NEWSWIRE)…
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics…
Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP),…
Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19
Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with…